Kornimate/medical-research-clean huggingface dataset:
optimal rtms for cognitive deficits and negative symptoms in schizophrenia

Conditions: Schizophrenia; Negative Symptoms in Schizophrenia; Cognitive Impairment; Repetitive Transcranial Magnetic Stimulation; Dorsolateral Prefrontal Cortex

Summary: negative symptoms and cognition decline are major challenges in clinical management of schizophrenia. dorsomedial prefrontal cortex (dlpfc) has been highly involved in the mechanisms of negative symptoms and cognitive symptoms of schizophrenia. however, the effect of repetitive transcranial magnetic stimulation (rtms) over left or bilateral dlpfc has not yet been well studied. the aim of this study is to describe how the effectiveness of rtms over different targets for cognitive deficits and negative symptoms in schizophrenia will be evaluated. the study will provide evidence to determine whether a bilateral dlpfc rtms and is more effective than a left dlpfc rtms alone to optimize treatment protocol in schizophrenia.

the study will be a randomized, double-blind trial comparing active rtms over bilateral dlpfc vs. active rtms over left dlpfc vs. sham rtms delivered over dlpfc an 4-week treatment period. after assessment and inclusion into the study, participants will be randomized to receive up to 20 sessions of either active rtms over left dlpfc or bilateral dlpfc or placebo treatments.

Eligibility criteria:
inclusion criteria: * met the diagnostic and statistical manual of mental disorders, five edition (dsm-v) diagnostic criteria for schizophrenia and the diagnosis was verified by an experienced psychiatrist based on the mini-international neuropsychiatric interview (mini) 7.0 . * age between 18 and 60. * patients with prominently negative symptoms, which was defined as: panss negative subscore≥15 points and one of items n1-n7 scoring≥4. * all patients were in stable clinical conditions (reduction rate of panss score\<10% within 4 weeks), stable antipsychotic treatment for at least 4 weeks, and able to provide informed consent. exclusion criteria: * any contraindication for rtms (e.g., intracranial metal, pacemakers, cochlear and intracranial hypertension). * unstable clinical condition (e.g., being aggressive and uncooperative). * current substance abuse. * any other psychiatric diagnosis. * significant medical condition including neurological disease, severe cardiovascular, hepatic, renal diseases. * previous treatment with modified electric convulsive therapy (mect) within 3 months before enrollment.
effects of complex decongestive therapy applied on patients with lower extremity lymphedema

Conditions: Lymphedema

Summary: the aim of this study is to investigate the effects of complex decongestive therapy applied to patients with lymphedema in the lower extremities on body awareness, functionality and quality of life.

lymphedema is a chronic condition characterized by the permanent accumulation of protein-rich fluid in certain body regions as a result of the dysfunction of the lymphatic system, in which skin and subcutaneous changes are added to the picture. pain in the affected extremity and other accompanying lymphedema symptoms can negatively affect functionality and quality of life, and swelling in the extremity can negatively affect the body image of individuals. today, complex decongestive therapy (cdt) is accepted as the gold standard in the treatment of lymphedema. it has been shown in the literature that cdt has positive effects on parameters such as functionality, quality of life, and balance in patients with upper limb lymphedema. there are few studies investigating the effects of cdt on body awareness, functionality and quality of life in patients who developed lymphedema in the lower extremities.

Eligibility criteria:
inclusion criteria: * be between the ages of 18-65 * having unilateral lymphedema in the lower extremity * volunteer to participate in the study exclusion criteria: * having bilateral lower extremity lymphedema * having an active infection * having a mental cognitive disorder * being unable to communicate and cooperate * conditions where manual lymphatic drainage is contraindicated (such as severe heart failure and/or uncontrolled rhythm disturbance, uncontrollable hypertension, being pregnant, presence of thrombus, active infection ect.) * presence of metastases
digital ischemia reduction in critically ill patients

Conditions: Hypovolemic Shock; Cardiogenic Shock; Digital Ischemia

Summary: patients requiring high dose pressors (minimum 2) who are unlikely to be weaned off them over 1 day will be identified. patients will have the device applied to one hand while expectant medical management will continue to the contralateral hand.

the proposed study offers no foreseeable risk to patients. the device relies on a wound vac system for vacuum generation which is industry standard and approved for creating safe suction applied to wounds. in this application, the same suction and device would be used to apply suction to an enclosure through which the hand is placed. similarly, a heat exchanger would be used to run lukewarm water through a warming bad, which is technology that is routinely used in surgery. heater coolers are used in every bypass surgery, and warming fluid blankets are common for helping to rewarm patients on the operating room table.

Eligibility criteria:
inclusion criteria: * patients in the cardiac critical care unit/cardiovascular intensive care unit with cardiac pathologies on vasopressor support exclusion criteria: * patients who are not on vasopressor support * patients under the age of 18
the possible role of thyroxine in keratoconus development

Conditions: Keratoconus

Summary: keratoconus (kc) is a corneal ectatic disorders, with incidence rate 1 per 50,000 among the population. hormonal imbalances may be associated with kc as it affects the corneal metabolism. in this study, we aim to examine this clinical association between thyroid gland dysfunction (tgd) and kc.

keratoconus (kc) is a corneal ectatic disorders, with incidence rate 1 per 50,000 among the population. moreover, the pathophysiological processes underlying kc have not been fully elucidated with proposed mechanisms to include proteolytic degradation in the corneal stroma, oxidative damage, epithelial mechanical injury, immunological factors, and genetic factors. however, hormonal imbalances may be associated with kc as it affects the corneal metabolism. furthermore, thyroid gland dysfunction (tgd) can frequently associated with eye diseases such as graves disease. previous studies investigated the association between tgd and kc. interestingly, thyroxine (t4) is important for corneal dehydration and transparency during embryonic development and regulates the synthesis of keratin sulfate proteoglycan in the chicken. t4 receptors (t4rs) have been found in the lacrimal gland, confirming that the tear producing gland is a target organ of t4. t4 level was elevated in the tears of patients with kc. hence, in this study, we aim to investigate the clinical association between tgd and kc.

Eligibility criteria:
inclusion criteria: * patients with kc. exclusion criteria: * patients who cannot give an informed consent. * patients who cannot provide needed samples for any reason
effectiveness of mm & kinesotaping in the female patients of ko to improve pain & functional mobility rct

Conditions: Knee Osteoarthritis

Summary: to find out the effectiveness of mobilization with movement and kinesotaping in the female patients of knee osteoarthritis to improve pain and functional mobility


Eligibility criteria:
inclusion criteria: * · female patients of age ranging from age above 50 years suffering from knee osteoarthritis will be included exclusion criteria: * · patients suffering from any type of cancer effecting area at which treatment will be applied. * patients having joint replacement or knee disease effecting the performance. * having skin allergies to taping.
the clinical efficacy of next science wound gel (nxtsc) in the healing of chronic wounds

Conditions: Wound Infection

Summary: determine the effect on wound treatment outcomes using a novel antimicrobial wound gel (nxtsc) for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site.

1. determine the effect on wound treatment outcomes using a novel antimicrobial wound gel (nxtsc) for the treatment of infected wounds as the sole topical treatment of microbial infection at the wound site. 2. determine the effect on wound treatment outcomes using a novel antimicrobial wound gel for the treatment of infected wounds when this gel is used in conjunction with the current standard of care infection controls to treat microbial infection at the wound site. 3. determine the effect on wound treatment outcomes using standard of care treatment. (soc).

Eligibility criteria:
inclusion criteria: 1. the subject must have a full-thickness chronic wound for greater than one month. 2. the subject must be at least 18 years of age. 3. the ulcer to be biopsied must be greater than 1 centimeter in area. 4. the subject must be able to give informed consent. exclusion criteria: 1. medical or emotional risk associated with the potential biopsy that outweighs the risk of not taking a biopsy as determined by the investigator. 2. those patients that have significant contributions from other disease processes such as arterial disease (ankle brachial index \[abi\] less than .7, or transcutaneous partial oxygen pressure \[tcpo2 \] less than 20) will be considered to have mixed vascular disease producing their wound and will be excluded from the study.
effects of reiki intervention during labor on pain, fear, and birth experience

Conditions: Labour

Summary: childbirth is an important and often stressful experience for many women, and labor pain is common among women. while labor pain is a natural part of the birth process, its severity and management can have a significant impact on an expectant mother's overall health and birth experience. studies examining the effects of reiki on alleviating the pain and fear experienced by pregnant women during labor are limited. in this context, understanding the effects of reiki practices in the birth process may be important for both clinical practice and future research.

failure to control pain can cause the mother to experience fear and stress, which can increase the risk of complications during labor and indirectly have negative effects on the newborn. there is a strong association between labor pain and fear. fear can increase the perception and intensity of pain, making the labor process more challenging and difficult to manage. this can negatively affect the mother's overall birth experience and complicate both the physical and emotional aspects of the birth process. a woman's birth experience also has an impact on her birth memory. a positive birth experience can cause a woman to evaluate the birth process as peaceful and satisfying, which positively shapes birth memory. the use of complementary and alternative therapies is increasing every year. although reiki has found application in various fields, there is no information in the available literature on its use in the management of labor pain. reiki is a complementary treatment method based on the "energy approach" and is generally recognized as safe and without side effects.

Eligibility criteria:
inclusion criteria: between the ages of 18 and 35, primiparous, singular primarily experiencing pregnancy, without risky pregnancy status (gdm, ht, etc.), during the birth week, literate speaks and understands turkish, 4 cm cervical dilatation - exclusion criteria: to have attended a childbirth preparation course, knowledge of coping with labor pain and fear of childbirth during pregnancy, presence of chronic disease in the mother, previous uterine surgery, having become pregnant through assisted reproductive technologies, hearing problems being diagnosed with a known serious psychiatric illness. -

Keywords: reiki, labour pain, delivery, birth experience, fear
study of vx-661 alone and in combination with ivacaftor in subjects homozygous or heterozygous to the f508del-cystic fibrosis transmembrane conductance regulator(cftr) mutation

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the safety, efficacy, pharmacokinetics (pk), and pharmacodynamics (pd) effects of vx-661 alone and when coadministered with ivacaftor in participants with cystic fibrosis (cf) who are homozygous or heterozygous for the f508del-cftr mutation.

this is a phase 2, randomized, multicenter, double-blinded, placebo-controlled, study of vx-661 monotherapy, and vx-661/ivacaftor co-therapy in participants with cf who are homozygous or heterozygous for the f508del cftr mutation. this study is separated into seven groups: group 1-7, respectively. approximately 180 participants were randomized in a ratio of 4:1; active drug to matching placebo in each group.

Eligibility criteria:
inclusion criteria: * male or female with confirmed diagnosis of cf * must have the f508del-cftr gene mutation in both alleles (groups 1, 2, 3, 4, 5, 6). group 7 participants must have the f508del-cftr mutation on 1 allele, and gating mutation g551d on the second allele and have been on their physician prescribed 150 mg kalydecotm q12h (commercially available ivacaftor) for at least 28 days at the screening visit. * forced expiratory volume in 1 second(fev1) 40% to 90% (inclusive) of predicted normal for age, gender, and height (knudson standards) at screening * weight \>40 kg and bmi \>18.5 * participants of child-bearing potential and who are sexually active must meet the contraception requirements. exclusion criteria: * history of any illness that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the participant. * an acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before study day 1. * history of solid organ or hematological transplantation * participation in a clinical study involving administration of either an investigational or a marketed drug within 30 days or 5 terminal half-lives (whichever is longer) before screening * history of alcohol, medication, or illicit drug abuse within 1 year prior to screening * pregnant, breast-feeding, or not willing to follow contraception requirements
aerosolized albuterol use in severe bpd

Conditions: Severe Bronchopulmonary Dysplasia

Summary: currently several dose schedules of albuterol are administered via nebulization to infants in the neonatal and infant intensive care unit (n/iicu). as albuterol is not fda approved for this population (under 2 years) there is no standard recommended dose. aerosolized albuterol is one of the most widely used therapies that are utilized for infants with chronic lung disease. the common practice in the n/iicu is weight base dosing of all medications. this contradicts the aerosol science recommendations, which advise not to titrate doses by weight as the patient naturally self-regulates their dose according to the change in minute ventilation with age. in addition, the wide use of aerosolized albuterol in the infant with bronchopulmonary dysplasia (bpd) has little current evidence of efficacy in this disease. understanding the appropriate dose for effective treatment as well as the indication for use in the bpd population would provide the clinician with useful guidelines. the investigators propose to analyze the safety and efficacy of aerosolized albuterol in infants with bpd comparing the recommended dose per aerosolization literature with the common dosing practices at the children's hospital of philadelphia (chop) as well as placebo.

this is a randomized, blinded cross-over study of infants with a diagnosis of severe bpd that are mechanically ventilated. participants will receive 3 sets of treatment (2.5mg albuterol, 1.25mg albuterol, 3ml normal saline placebo), in random order. each treatment will be administered every 4 hours for 24 hours. after a 6 hour washout phase, the next group of interventions will be applied. following another wash-out phase, the final group of intervention will be applied. pulmonary mechanics from the ventilator (e.g. airway compliance, airway resistance, tidal volume, peak inspiratory pressure, forced expiratory flow at 75% of forced vital capacity, etc.) and the patient short term response to therapy (heart rate, blood pressure, heart rhythm) will be assessed for the duration of the treatment period.

Eligibility criteria:
inclusion criteria: 1. infants greater than or equal to 36 weeks corrected gestational age to one year of age 2. diagnosis of bpd in accordance with the eunice kennedy shriver national institute of child health and human development (nichd) definition 3. may have a current order for short acting bronchodilator, not required 4. may have congenital anomalies unless one or more of the exclusion criteria are met, not required 5. receiving conventional mechanical ventilation via an artificial airway (endotracheal tube or tracheostomy) via draeger v500 ventilator 6. parental/guardian permission (informed consent) exclusion criteria: 1. airway leak greater than 10% 2. unilateral lung disease 3. current order for inhaled anticholinergic (i.e. ipratropium bromide) 4. active pulmonary or systemic infection 5. scheduled order for other medication that cause bronchodilation (i.e. atrovent, magnesium sulfate, ketamine, etc.)
a post-market study of use of the omni® surgical system in open angle glaucoma

Conditions: Glaucoma, Open-Angle

Summary: to prospectively compare the clinical effect of the omni surgical system in eyes with open angle glaucoma.

first, to prospectively compare the clinical effect of the transluminal viscoelastic delivery and trabeculotomy using the omni surgical system to the istent inject used with cataract extraction in eyes with open angle glaucoma (oag) and second, to prospectively compare the clinical effect of the transluminal viscoelastic delivery using the omni surgical system to the istent inject used with cataract extraction in eyes with open angle glaucoma (oag)

Eligibility criteria:
inclusion criteria: * male or female subjects, 22 years or older * visually significant cataract * mild to moderate open angle glaucoma * on 1-5 iop-lowering medications * potential of good best corrected visual acuity post cataract extraction, in the investigator's judgment * able and willing to comply with the protocol, including all follow-up visits. * understand and sign the informed consent. exclusion criteria: * any of the following prior treatments for glaucoma: * laser trabeculoplasty ≤3 months prior to baseline * implanted with istent (all types), cypass, xen, express, glaucoma draining device/valve, or hydrus device * prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy, ecp or cpc * acute angle closure, normal tension, traumatic, congenital, malignant, uveitic, neovascular or severe glaucoma as documented in subjects' medical record. * concurrent ocular pathology or systemic medical condition which, in the investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period (e.g., wet amd, corneal edema, fuch's dystrophy, active intraocular infection or inflammation within 30 days prior to screening visit, etc.), or interfere with compliance to elements of the study protocol (e.g., returning to investigator's office for follow-up visits). * participation (≤ 30 days prior to baseline) in an interventional trial which could have a potential effect on the study outcome, as determined by the study investigator * women of childbearing potential if they are currently pregnant or intend to become pregnant during the study period; are breast-feeding; or are not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
six month plaque and gingivitis study using colgate total toothpaste

Conditions: Dental Plaque; Gingivitis

Summary: the objective of this randomized, single center, parallel clinical research study is to evaluate the comparative efficacy performance of three dentifrices -colgate total toothpaste, parodontax toothpaste and colgate cavity protection toothpaste in controlling gingivitis and dental plaque in adults.


Eligibility criteria:
inclusion criteria: 1. subjects, ages 18-70, inclusive. 2. availability for the six-month duration ofthe clinical research study. 3. good general health. 4. minimum of 20 uncrowned permanent natural teeth (excluding third molars). 5. initial gingivitis index of at least 1.0 as determined by the use of the loe and silness gingival index. 6. initial plaque index of at least 1.5 as determined by the use of the quigley and hein plaque index (turesky modification). 7. signed informed consent form. exclusion criteria: 1. presence of orthodontic bands. 2. presence of partial removable dentures. 3. tumor(s) of the soft or hard tissues of the oral cavity. 4. advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). 5. five or more carious lesions requiring immediate restorative treatment. 6. antibiotic use any time during the one month prior to entry into the study. 7. participation in any other clinical study or test panel within the one month prior to entry into the study. 8. dental prophylaxis during the past two weeks prior to baseline examinations. 9. history of allergies to oral care/personal care consumer products or their ingredients. 10. on any prescription medicines that might interfere with the study outcome. 11. an existing medical condition which prohibits eating or drinking for periods up to 4 hours. 12. history of alcohol or drug abuse. 13. pregnant or lactating subjects.
the attractive 2 trial - pharmacokinetics of atr-258 oral capsule vs. oral solution formulations in healthy volunteers

Conditions: Type2diabetes

Summary: this is a single-centre, open-label, randomised, 2-period cross-over, phase 1 comparative trial to assess the atr-258 pharmacokinetic (pk) parameters of an oral capsule formulation in comparison with an oral solution formulation, both given as single doses to healthy volunteers. the order of treatment, i.e., the treatment sequence capsule - solution or solution - capsule, will be randomised.


Eligibility criteria:
inclusion criteria: * provision of informed consent * body mass index ≥ 18.5 and ≤ 30.0 * medically healthy participant * willing to use of double barrier contraceptive method if of childbearing potential exclusion criteria: * history or clinical manifestation of any clinically significant disease * history of dysphagia or any other swallowing disorder * current smokers or users of nicotine products * history or manifestation of drug abuse, alcohol abuse and/or excessive intake of alcohol